Facebook
Instagram
Linkedin
Pinterest
Twitter
Youtube
Home
Safe Snack Guide
Peanut and Tree Nut Free Edition
Milk Free Edition
Sesame Free Edition
Gluten Free Edition
Custom Edition
Allergence
Coupons
About Us
Media Kit
Advertising Guide
Manufacturer Partnership
Subscribe to our newsletter
Contact Us
Resources
FAQ
Tools for Schools
Coupons
Search
Home
Safe Snack Guide
Peanut and Tree Nut Free Edition
Milk Free Edition
Sesame Free Edition
Gluten Free Edition
Custom Edition
Allergence
Coupons
About Us
Media Kit
Advertising Guide
Manufacturer Partnership
Subscribe to our newsletter
Contact Us
Resources
FAQ
Tools for Schools
Coupons
Search
Tag: PVX108
Aravax Doses First Patient in Phase 2 Peanut Allergy Clinical Trial
News Wire ~ 3rd Party Press Release
-
2023/06/01
PVX108 does not contain peanut proteins which put patients at risk of serious side effects.
FDA Green Lights Phase 2 Trials of PVX108, a Novel Peptide-Driven...
News Wire ~ 3rd Party Press Release
-
2022/03/04
Phase 2 study of candidate from Aravax will commence in the US and Australia.
Aravax Presents Additional Positive Phase I Trial Results for PVX108, a...
News Wire ~ 3rd Party Press Release
-
2019/06/05
Trial results demonstrate excellent PVX108 safety profile in patients with prior anaphylaxis and current asthma.
Phase I Trial for New Peanut Allergy Immunotherapy Results in No...
Dave Bloom
-
2019/02/24
Research details phase one study of peptide-based immunotherapy, which is designed to remove risks of acute reactions during treatment.
Novel Peanut Allergy Vaccine Begins Phase I Clinical Trials
Dave Bloom
-
2017/05/22
Vaccine uses peptides selected from parts of the peanut protein that do not cause life-threatening anaphylactic reactions.